PYRROLOPYRIMIDINES USED AS PROTEIN KINASE INHIBITORS

FIELD: chemistry. ^ SUBSTANCE: invention relates to novel pyrrolopyrimidines of general formula (I) or pharmaceutically acceptable salts thereof, having JANUS: JAK2, JAK3 protein kinase, protein kinase A (PKA), serine/threonine protein kinase ROCK inhibiting properties. The compounds can be used to treat such diseases as allergy, asthma, atopic dermatitis and others. In structural formula (I): R1 denotes H; R2 denotes H; Z1 denotes C1-6aliphatic group or C5-7cycloaliphatic group, optionally substituted with 0-1 groups Jz; if the bond between Z1 and C is a double bond, then Z1 can also denote =O or =C(R)2; Z2 denotes H; or C1-10halogenalkyl, -(Vn)-CN, (Vn)-(heterocyclyl), where the heterocyclyl is a 6-member ring containing a nitrogen atom or two oxygen atoms as heteroatoms, -(Vn)-(phenyl) or -(Vn)-(C3-10cycloaliphatic group), optionally substituted with 0-1 groups Jz; or Z1 and Z2 together with the carbon atom with which they are bonded form a ring Q; Z3 denotes H or C1-6alkyl, optionally substituted with 0-1 groups Jz; or Z1, Z2 and Z3 together with the carbon atom with which they are bonded form a 6-8-member saturated bicyclic ring Q; where if the bond between Z1 and C is a triple bond, then Z2 and Z3 are absent; if the bond between Z1 and C is a double or triple bond, then Z3 is absent or Z2 and Z3 are absent; Q denotes a 3-8-member saturated or partially saturated monocyclic ring containing 0-2 heteroatoms selected from nitrogen, oxygen or sulphur, where said Q is optionally and independently condensed with Q1; where said Q is optionally substituted with 0-4 groups JQ, where said Q is optionally substituted with 0-4 groups JQ. Values of other radicals are given in the claim. ^ EFFECT: high efficiency of using the compositions. ^ 35 cl, 5 dwg, 5 tbl, 14 ex Настоящее изобретение относится к новым пирролопиримидинам общей формулы (I) или их фармацевтически приемлемым солям, обладающим свойствами ингибиторов протеинкиназ семейства JANUS: JAK2, JAK3, протеинкиназы А (РКА), семейства серин/треонин протеинкиназы ROCK. Соединения могут найти применение для лечения таких заболеваний, как аллергия, астма, атопический дерматит и др. В структурной ! формуле (I): ! ! R1 представляет собой H; R2 представляет собой H; Z1 представляет собой С1-6алифатическую группу или С5-7циклоалифатическую группу, необязательно замещенные 0-1 группами JZ; если связь между Z1 и С является двойной, то Z1 может также представлять собой =O или =C(R)2; Z2 представляет собой Н; или С1-10а